KaloCyte, Inc.

Interested in what is happening with prehospital blood transfusions? Our webpage has many useful resources including presentations from past meetings. Join our mailing list for meeting information and opportunities to participate! https://lnkd.in/e9zwxXZ2 #prehospital #EMS #HEMS #blood #bloodbank #trauma #maternalhealth #blooddonation #medicalemergencies

Congratulations to our research partner, investor and landlord, the University of Maryland, Baltimore (UMB), designated today a Research 1 (R1) Institution by the American Council of Education (ACE) and the Carnegie Classification of Institutions of Higher Education (Carnegie Foundation). And yes, that's co-founder Allan Doctor observing KaloCyte, Inc.'s #ErythroMer biosynthetic RBC substitute in development to treat severe blood loss when blood is not available. https://lnkd.in/efK5CtwW

Congratulations to our research partner, investor and landlord, the University of Maryland, Baltimore (UMB), designated today a Research 1 (R1) Institution by the American Council of Education (ACE) and the Carnegie Classification of Institutions of Higher Education (Carnegie Foundation). And yes, that's co-founder Allan Doctor observing KaloCyte, Inc.'s #ErythroMer biosynthetic RBC substitute in development to treat severe blood loss when blood is not available. https://lnkd.in/efK5CtwW

The Long Quest for Artificial Blood: One of the most valuable substances in the world has never been replicated. Are we close? KaloCyte’s three co-founders, Drs. Allan Doctor (CSO), Prof. Dipanjan Pan (CTO), and Phil Spinella (CMO) were among several experts interviewed for and quoted in Nicola Twilley's The New Yorker article on the history and current status blood substitute research, featuring KaloCyte’s development of ErythroMer. https://lnkd.in/eTDKCP4e University of Maryland School of Medicine, Penn State University, University of Pittsburgh, John Holcomb, Jean-Paul Chretien, Defense Advanced Research Projects Agency (DARPA)

Big news! KaloCyte, Inc. has been selected to join?Blue Knight, a strategic collaboration between the?Biomedical Advanced Research and Development Authority (BARDA) and Johnson & Johnson’s global incubator network, JLABS, supporting early-stage innovation and incubation of science and technologies to improve health security and unlock new approaches to solving health issues. KaloCyte, a University of Maryland BioPark affiliate, will be a virtual resident within?JLABS, a premier life science incubator program. We will keep their laboratories and offices in downtown Baltimore where we collaborate closely with the University of Maryland, Baltimore (UMB)’s Center for Blood Oxygen Transport & Hemostasis (CBOTH). “We are thrilled to join JLABS and the Blue Knight program and look forward to working alongside industry leaders, BARDA, and other?Blue Knight companies,” commented KaloCyte President and CEO, Elaine Haynes. “We are at a critical stage, preparing for an investigational new drug filing. The regulatory expertise and guidance available through the Blue Knight community will help ensure our development stays aligned with stakeholder interests.” https://lnkd.in/ecBeWkPr

KaloCyte, Inc. has a new collaborator in the mix: the expert #biomanufacturing team at Scorpius BioManufacturing, Inc.. The Scorpius team will be instrumental in scaling our #ErythroMer artificial RBC substitute as we advance towards the clinic. Their work is expected to build upon the existing activities at KaloCyte and with our developmental partners on the DARPA FSHARP program. Joseph Payne, Shari Udoff-McDonald

KaloCyte, Inc. has benefited greatly from not only the multiple NIH grants, but also the myriad of support programs that support our commercialization development and conference attendance. Thank you, Anna Zornosa, Chris S., Stephanie M. Davis, Ph.D. and NIH SEED! The National Institutes of Health.

Every innovation story matters. If you’ll be at #JPM2025, come to at WuXi AppTec's #WuXiGlobalForum Executive Roundtables on 1/15/24 to see how we’re bringing real change for patients around the world. https://lnkd.in/eJ5m3X_j. At 3:45pm, our CEO Elaine Haynes will share KaloCyte, Inc.'s development of Artificial Blood: Derisking Therapeutic Development Through Non-Dilutive Funding and Intensive Stakeholder Alignment Check out our Highlight Video here: https://lnkd.in/e8kpiuBh Request an invite here: https://lnkd.in/eDz4yEty

Heading to SF for JPM next week? Me too! Here's a few of my currently planned events and partnering - hope to see you there! Springboard Enterprises Breakfast, 1/13 (I am a proud alumnus of the 2020 Lifesciences cohort). https://lnkd.in/gYi7YPxb WuXi AppTec Wuxi Global Forum 2025, 1/14 1:30-7:00pm PT. KaloCyte is hosting one of the CEO Roundtables at 3:45. (Hilton SF Union Square). https://lnkd.in/gX78zZuA CSSi LifeSciences Partnering Forum (Hilton SF Union Square). Registration is free, schedule meetings with me through their partnering app. https://lnkd.in/gEzzpPpv Maryland Tech Council meeting space (Hilton SF Union Square), sponsored by BioHub Maryland, Maryland Department of Commerce and @Montgomery County Economic Development Corporation. Bullpen, Golden Gate Yacht Club https://bullpen.club/ And many of the breakfasts and evening receptions…

Congratulations to KaloCyte Advisor Greg Lanza for his election as a Fellow of the National Academy of Inventors! Dr. Lanza was instrumental in KaloCyte's product design and company formation. Well earned!